Cargando…
International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials
In June 2021, the US Food and Drug Administration (FDA) released a draft guidance for industry on core patient-reported outcomes (PROs) and related considerations for instrument selection and trial design in registrational cancer clinical trials, building on prior communications about the use of PRO...
Autores principales: | Brady, Keri J. S., Peipert, John Devin, Atkinson, Thomas M., Pompili, Cecilia, Pinto, Monica, Shaw, James W., Roydhouse, Jessica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202747/ https://www.ncbi.nlm.nih.gov/pubmed/37217665 http://dx.doi.org/10.1007/s11136-023-03396-z |
Ejemplares similares
-
The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary
por: Darpo, Borje, et al.
Publicado: (2021) -
How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration
por: Furlong, Pat, et al.
Publicado: (2015) -
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
Publicado: (2006) -
Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”
por: de Vlieger, Jon S. B., et al.
Publicado: (2019) -
Is COVID-19 pushing us to the Fifth Industrial Revolution (Society 5.0)?
por: Sarfraz, Zouina, et al.
Publicado: (2021)